Home The Word Brain	My Amedeo FAQ Privacy About
	C49 + CC Journal Club For more information, please refer to our special emails from April 13 and May 19.

Hepatitis C

Free Subscription Articles published in J Gastroenterol Retrieve available abstracts of 9 articles: HTML format

Single Articles

February 2025
1. WATANABE T, Tokumoto Y, Ochi H, Mashiba T, et al
   Clinical factors to predict changes of esophagogastric varices after sustained viral response with direct-acting antiviral therapy.
   J Gastroenterol. 2025;60:222-234.
   PubMed     Abstract available
   
   
   November 2024
2. IWAMOTO T, Nozaki Y, Inoue T, Suda T, et al
   Histological improvement of fibrosis in patients with hepatitis C who achieved a 5-year sustained virological response to treatment with direct-acting antivirals.
   J Gastroenterol. 2024 Nov 25. doi: 10.1007/s00535-024-02165.
   PubMed     Abstract available
   
   
   September 2024
3. YAMAUCHI K, Maekawa S, Osawa L, Komiyama Y, et al
   Single-molecule sequencing of the whole HCV genome revealed envelope deletions in decompensated cirrhosis associated with NS2 and NS5A mutations.
   J Gastroenterol. 2024 Sep 3. doi: 10.1007/s00535-024-02146.
   PubMed     Abstract available
   
   
   May 2024
4. SUZUKI T, Matsuura K, Nagura Y, Ito K, et al
   MicroRNA-223-3p levels in serum-derived extracellular vesicles predict regression of M2BPGi-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents.
   J Gastroenterol. 2024 May 13. doi: 10.1007/s00535-024-02115.
   PubMed     Abstract available
   
   
   
5. ATSUKAWA M, Tsubota A, Kondo C, Toyoda H, et al
   ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis.
   J Gastroenterol. 2024 May 10. doi: 10.1007/s00535-024-02109.
   PubMed     Abstract available
   
   
   April 2024
6. LIU CH, Chang YP, Fang YJ, Cheng PN, et al
   Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals.
   J Gastroenterol. 2024 Apr 13. doi: 10.1007/s00535-024-02101.
   PubMed     Abstract available
   
   
   December 2023
7. UOJIMA H, Nakabayashi K, Yamasaki K, Sugiyama M, et al
   New chemiluminescent enzyme immunoassay for quantitative measurement of Mac-2 binding protein glycosylation isomer in chronic liver disease.
   J Gastroenterol. 2023;58:1252-1260.
   PubMed     Abstract available
   
   
   October 2023
8. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
   Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.
   J Gastroenterol. 2023 Oct 13. doi: 10.1007/s00535-023-02039.
   PubMed     Abstract available
   
   
   March 2023
9. SHIMAKAMI T, Setoyama H, Oza N, Itakura J, et al
   Development of performance indicators for hepatitis countermeasures as a tool for the assessment and promotion of liver cancer prevention in Japan.
   J Gastroenterol. 2023;58:257-267.
   PubMed     Abstract available
   
   

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge.